Northridge, Calif. and Centennial, Colo. — Oct. 25, 2016 — TheraCell, a regenerative medicine company, today announced that the United States Patent and Trademark Office (USPTO) will issue TheraCell a patent for its demineralized bone fiber (DBF) technology. The addition of this patent expands TheraCell’s patent portfolio, demonstrating its ongoing commitment to innovation and leadership in the orthopedic allograft industry.

TheraCell’s DBF technology is incorporated into two new innovative demineralized cortical fiber allografts, AlloFuse® Cortical Fibers and AlloFuse® Fiber Boats, provided by AlloSource®, one of the nation’s largest providers of cartilage, cellular, bone, skin and soft-tissue allografts. AlloFuse Cortical Fibers and AlloFuse Fiber Boats can be used in a variety of spine and orthopedic procedures. Both products consist of 100 percent demineralized cortical bone and provide exceptional handling characteristics for bone fusion procedures.

“We are tremendously pleased that the USPTO has notified us of the issuance of this patent for our DBF technology. Our technology for fibers with highly controlled geometry allows us exceptional capabilities for developing a broad range of products. We are intently focused on providing disruptive products for bone healing and other indications,” said TheraCell Chief Science Officer, Nelson Scarborough, Ph.D.

“Collaborating with TheraCell provides a great opportunity for us to incorporate this new technology into our AlloFuse product portfolio,” said AlloSource Chief Commercial Officer, Kerr Holbrook. “We are seeing a shift to fiber-based allografts and are proud to offer this solution to our surgeons and their patients.”